Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
6(55%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
4
36%
Ph phase_3
3
27%
Ph not_applicable
1
9%

Phase Distribution

0

Early Stage

4

Mid Stage

3

Late Stage

Phase Distribution8 total trials
Phase 2Efficacy & side effects
4(50.0%)
Phase 3Large-scale testing
3(37.5%)
N/ANon-phased studies
1(12.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

6

trials recruiting

Total Trials

11

all time

Status Distribution
Active(8)
Completed(1)
Other(2)

Detailed Status

Recruiting5
unknown2
Not yet recruiting2
Active, not recruiting1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
6
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 24 (50.0%)
Phase 33 (37.5%)
N/A1 (12.5%)

Trials by Status

active_not_recruiting19%
recruiting545%
unknown218%
completed19%
not_yet_recruiting218%

Recent Activity

6 active trials
Showing 5 of 11
not_yet_recruitingphase_2

Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging

NCT07527806
active_not_recruitingphase_2

Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression

NCT04920708
recruitingphase_2

An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy

NCT07117630
recruiting

Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer

NCT07180056
recruitingphase_2

Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer

NCT07180160
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT07527806Phase 2

Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging

Not Yet Recruiting
NCT04920708Phase 2

Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression

Active Not Recruiting
NCT07117630Phase 2

An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy

Recruiting
NCT07180056

Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer

Recruiting
NCT07180160Phase 2

Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer

Recruiting
NCT07005557Phase 3

Chemo-free in Older (≥65) Node-Positive ER+/HER2- Breast Cancer

Not Yet Recruiting
NCT06558084

Real-World Clinical Outcomes and Toxicity in Metastatic Breast Cancer Patients Treated With First or Second Line CDK 4/6 Inhibitors and Endocrine Therapy

Completed
NCT06447623Phase 3

Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer

Recruiting
NCT05795335

CDK4/6 Inhibitors in Patients With Hormone Receptor-positive Advanced Breast Cancer

Recruiting
NCT05295043Not Applicable

Advanced Breast Cancer Study of CDK4/6 Inhibitor Combined With Endocrine Therapy Endocrine Therapy in HR+/HER2- Advanced Breast Cancer

Unknown
NCT05429684Phase 3

Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

Unknown

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11